Salvage stereotactic body radiotherapy (SBRT) for intraprostatic relapse after prostate cancer radiotherapy: An ESTRO ACROP Delphi consensus

BA Jereczek-Fossa, G Marvaso, M Zaffaroni… - Cancer treatment …, 2021 - Elsevier
Background and purpose Between 30% and 47% of patients treated with definitive
radiotherapy (RT) for prostate cancer are at risk of intraprostatic recurrence during follow-up …
被引用次数：34 相关文章

Salvage stereotactic body radiotherapy (SBRT) for intraprostatic relapse after prostate cancer radiotherapy: An ESTRO ACROP Delphi consensus.

BA Jereczek-Fossa, G Marvaso, M Zaffaroni… - Cancer treatment …, 2021 - boris.unibe.ch
BACKGROUND AND PURPOSE Between 30% and 47% of patients treated with definitive
radiotherapy (RT) for prostate cancer are at risk of intraprostatic recurrence during follow-up …

Salvage stereotactic body radiotherapy (SBRT) for intraprostatic relapse after prostate cancer radiotherapy: An ESTRO ACROP Delphi consensus

BA Jereczek-Fossa, G Marvaso… - Cancer treatment …, 2021 - pubmed.ncbi.nlm.nih.gov
Background and purpose Between 30% and 47% of patients treated with definitive
radiotherapy (RT) for prostate cancer are at risk of intraprostatic recurrence during follow-up …

Salvage stereotactic body radiotherapy (SBRT) for intraprostatic relapse after prostate cancer radiotherapy: An ESTRO ACROP Delphi consensus

B Jereczek-Fossa, G Marvaso… - Cancer Treatment …, 2021 - hal-emse.ccsd.cnrs.fr
Salvage stereotactic body radiotherapy (SBRT) for intraprostatic relapse after prostate cancer
radiotherapy: An ESTRO ACROP Delphi consensus - Centre de recherche Saint-Antoine …

Salvage stereotactic body radiotherapy (SBRT) for intraprostatic relapse after prostate cancer radiotherapy: An ESTRO ACROP Delphi consensus.

BA Jereczek-Fossa, G Marvaso, M Zaffaroni… - 2022 - repository.icr.ac.uk
Background and purpose Between 30% and 47% of patients treated with definitive
radiotherapy (RT) for prostate cancer are at risk of intraprostatic recurrence during follow-up …

Salvage stereotactic body radiotherapy (SBRT) for intraprostatic relapse after prostate cancer radiotherapy: An ESTRO ACROP Delphi consensus

B Jereczek-Fossa, G Marvaso… - Cancer Treatment …, 2021 - univ-fcomte.hal.science
Salvage stereotactic body radiotherapy (SBRT) for intraprostatic relapse after prostate cancer
radiotherapy: An ESTRO ACROP Delphi consensus - Université de Franche-Comté Accéder …

[引用][C] Salvage stereotactic body radiotherapy (SBRT) for intraprostatic relapse after prostate cancer radiotherapy: An ESTRO ACROP Delphi consensus

BA Jereczek-Fossa, G Marvaso, M Zaffaroni… - 2021 - repository.ubn.ru.nl
BACKGROUND AND PURPOSE: Between 30% and 47% of patients treated with definitive
radiotherapy (RT) for prostate cancer are at risk of intraprostatic recurrence during follow-up …

Salvage stereotactic body radiotherapy (SBRT) for intraprostatic relapse after prostate cancer radiotherapy: An ESTRO ACROP Delphi consensus

BA Jereczek-Fossa, G Marvaso, M Zaffaroni… - 2021 - christie.openrepository.com
Background and purpose: Between 30% and 47% of patients treated with definitive
radiotherapy (RT) for prostate cancer are at risk of intraprostatic recurrence during follow-up …

Salvage stereotactic body radiotherapy (SBRT) for intraprostatic relapse after prostate cancer radiotherapy: An ESTRO ACROP Delphi consensus

B Jereczek-Fossa, G Marvaso… - Cancer Treatment …, 2021 - univ-tours.hal.science
Salvage stereotactic body radiotherapy (SBRT) for intraprostatic relapse after prostate cancer
radiotherapy: An ESTRO ACROP Delphi consensus - Université de Tours Accéder …

Salvage stereotactic body radiotherapy (SBRT) for intraprostatic relapse after prostate cancer radiotherapy: An ESTRO ACROP Delphi consensus

BA Jereczek-Fossa, G Marvaso… - CANCER …, 2021 - re.public.polimi.it
Background and purpose: Between 30% and 47% of patients treated with definitive
radiotherapy (RT) for prostate cancer are at risk of intraprostatic recurrence during follow-up …